H Liu1, R Baliga. 1. Department of Pediatrics, Division of Nephrology, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216-4505, USA.
Abstract
BACKGROUND: Iron catalyzed reactive oxygen metabolites (ROM) are important mediators in cisplatin (CP)-induced nephrotoxicity, and cytochrome P450 (CYP) is the major source of this iron. Iron chelators, hydroxyl radical scavengers and CYP inhibitors have shown marked protection. MATERIAL AND METHODS: This study was designed to determine whether these agents affect the tumoricidal efficacy of CP to LLC-WRC 256 tumor cells. RESULTS: CP was cytotoxic to the tumor cells in a dose and time dependent manner. Iron chelator, hydroxyl radical scavenger and CYP inhibitors did not reduce the cytotoxic effect of CP. Exposure of the tumor cells to CP did not increase the catalytic iron release and the generation of hydroxyl radical. Both CYP activity and content in the tumor cells were less than 10% of that in the rat liver. CONCLUSION: We speculate that iron chelator, hydroxyl radical scavenger and CYP inhibitors do not alter the antitumor efficacy of CP.
BACKGROUND:Iron catalyzed reactive oxygen metabolites (ROM) are important mediators in cisplatin (CP)-induced nephrotoxicity, and cytochrome P450 (CYP) is the major source of this iron. Iron chelators, hydroxyl radical scavengers and CYP inhibitors have shown marked protection. MATERIAL AND METHODS: This study was designed to determine whether these agents affect the tumoricidal efficacy of CP to LLC-WRC 256 tumor cells. RESULTS: CP was cytotoxic to the tumor cells in a dose and time dependent manner. Iron chelator, hydroxyl radical scavenger and CYP inhibitors did not reduce the cytotoxic effect of CP. Exposure of the tumor cells to CP did not increase the catalytic iron release and the generation of hydroxyl radical. Both CYP activity and content in the tumor cells were less than 10% of that in the rat liver. CONCLUSION: We speculate that iron chelator, hydroxyl radical scavenger and CYP inhibitors do not alter the antitumor efficacy of CP.